ERBB2 and breast carcinoma: There has been a greater interest in the use of liposomal anthracyclines in early breast cancer overexpressing HER2 oncogene, as this subgroup of patients could obtain the greatest benefit from treatment with anthracyclines [67] and combining them with trastuzumab may be difficult due to the high cardiotoxicity that could be induced.